A Study To Investigate Markers Of Inflammation In Rheumatoid Arthritis

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Osteoarthritis; Rheumatoid Arthritis

Treatments: Procedure: High frequency ultrasonography; Procedure: Power doppler ultrasonography; Procedure: Exhaled nitric oxide assessment

Study type: Observational

Funder types: Industry

Identifiers

NCT00242853

RA4102651

Details and patient eligibility

About

This study is being conducted to validate various biomarkers in patients with RA with varying levels of disease severity. Subjects with a diagnosis of rheumatoid arthritis (RA) will be included as controls. The sudy will measure the baseline levels and the intra- and inter-subject variability of exhaled nitric oxide (NO) in patients with inactive/mild and moderate/severe RA on stable therapy or during a course glucocorticoids. In addition exhaled NO levels will be correlated with intra-articular inflammation (power Doppler ultrasonography) as well as markers of systemic inflammation (CRP, ESR).

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of rheumatoid or osteo-arthritis.
• Weight greater than 45kg (females) or 50kg (males) but not overweight.
• Non-smokers.
• Taking stable anti-inflammatory medication for Rheumatoid Arthritis (RA) or Osteoarthritis (OA) for at least 8 weeks.

Exclusion criteria

• Taking regular doses of glucocorticoid medication (greater than 5mg/day).
• Currently taking biological treatment for RA.
• Recent participation in another clinical trial.